Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1-2/2013

01-06-2013

Reconstructing skin cancers using animal models

Authors: Michael D. Gober, Hasan M. Bashir, John T. Seykora

Published in: Cancer and Metastasis Reviews | Issue 1-2/2013

Login to get access

Abstract

The American Cancer Society estimates that skin cancer is the most prevalent of all cancers with over 2 million cases of nonmelanoma skin cancer each year and 75,000 melanoma cases in 2012. Representative animal cancer models are important for understanding the underlying molecular pathogenesis of these cancers and the development of novel targeted anticancer therapeutics. In this review, we will discuss some of the important animal models that have been useful to identify important pathways involved in basal cell carcinoma, squamous cell carcinoma, and melanoma.
Literature
1.
Rubin, A. I., Chen, E. H., & Ratner, D. (2005). Basal-cell carcinoma. The New England Journal of Medicine, 353(21), 2262–2269.PubMedCrossRef
2.
Zhang, M., Qureshi, A. A., Geller, A. C., Frazier, L., Hunter, D. J., & Han, J. (2012). Use of tanning beds and incidence of skin cancer. Journal of Clinical Oncology, 30(14), 1588–1593.PubMedCrossRef
3.
Howell, J. B., & Caro, M. R. (1959). The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development. Archives of Dermatology, 79(1), 67–80.PubMedCrossRef
4.
Gorlin, R. J., & Goltz, R. W. (1960). Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. The New England Journal of Medicine, 262(18), 908–912.PubMedCrossRef
5.
Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., et al. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell, 85(6), 841–851.PubMedCrossRef
6.
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., et al. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science, 272(5268), 1668–1671.PubMedCrossRef
7.
Gailani, M. R., Stahle-Backdahl, M., Leffell, D. J., Glyn, M., Zaphiropoulos, P. G., Unden, A. B., et al. (1996). The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nature Genetics, 14(1), 78–81. doi:10.​1038/​ng0996-78.PubMedCrossRef
8.
Kasper, M., Jaks, V., Hohl, D., & Toftgård, R. (2012). Basal cell carcinoma—molecular biology and potential new therapies. The Journal of Clinical Investigation, 122(2), 455–463.PubMedCrossRef
9.
Hooper, J. E., & Scott, M. P. (1989). The Drosophila patched gene encodes a putative membrane protein required for segmental patterning. Cell, 59(4), 751–765.PubMedCrossRef
10.
Lum, L., & Beachy, P. A. (2004). The hedgehog response network: sensors, switches, and routers. Science, 304(5678), 1755–1759.PubMedCrossRef
11.
Oro, A. E., Higgins, K. M., Hu, Z., Bonifas, J. M., Epstein, E. H., & Scott, M. P. (1997). Basal cell carcinomas in mice overexpressing sonic hedgehog. Science, 276(5313), 817–821.PubMedCrossRef
12.
Xie, J., Murone, M., Luoh, S.-M., Ryan, A., Gu, Q., Zhang, C., et al. (1998). Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature, 391(6662), 90–92. doi:10.​1038/​34201.PubMedCrossRef
13.
Nilsson, M., Undèn, A. B., Krause, D., Malmqwist, U., Raza, K., Zaphiropoulos, P. G., et al. (2000). Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proceedings of the National Academy of Sciences of the United States of America, 97(7), 3438–3443.PubMedCrossRef
14.
Grachtchouk, M., Mo, R., Yu, S., Zhang, X., Sasaki, H., Hui, C.-c., et al. (2000). Basal cell carcinomas in mice overexpressing Gli2 in skin. Nature Genetics, 24(3), 216–217. doi:10.​1038/​73417.PubMedCrossRef
15.
Aszterbaum, M., Epstein, J., Oro, A., Douglas, V., LeBoit, P. E., Scott, M. P., et al. (1999). Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nature Medicine, 5(11), 1285–1291. doi:10.​1038/​15242.PubMedCrossRef
16.
Grachtchouk, V., Grachtchouk, M., Lowe, L., Johnson, T., Wei, L., Wang, A., et al. (2003). The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO Journal, 22(11), 2741–2751. doi:10.​1093/​emboj/​cdg271.PubMedCrossRef
17.
Ramírez, A., Bravo, A., Jorcano, J. L., & Vidal, M. (1994). Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation, 58(1), 53–64.PubMed
18.
Youssef, K. K., Van Keymeulen, A., Lapouge, G., Beck, B., Michaux, C., Achouri, Y., et al. (2010). Identification of the cell lineage at the origin of basal cell carcinoma. Nature Cell Biology, 12(3), 299–305. doi:10.​1038/​ncb2031.PubMed
19.
Wong, S. Y., & Reiter, J. F. (2011). Wounding mobilizes hair follicle stem cells to form tumors. Proceedings of the National Academy of Sciences, 108(10), 4093–4098.CrossRef
20.
Kasper, M., Jaks, V., Are, A., Bergström, Å., Schwäger, A., Svärd, J., et al. (2011). Wounding enhances epidermal tumorigenesis by recruiting hair follicle keratinocytes. Proceedings of the National Academy of Sciences, 108(10), 4099–4104.CrossRef
21.
Ratushny, V., Gober, M. D., Hick, R., Ridky, T. W., & Seykora, J. T. (2012). From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. The Journal of Clinical Investigation, 122(2), 464–472.PubMedCrossRef
22.
Cockerell, C. J. (2000). Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). Journal of the American Academy of Dermatology, 42(1), S11–S17.CrossRef
23.
Marks, R., Rennie, G., & Selwood, T. S. (1988). Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet, 1(8589), 795–797.PubMedCrossRef
24.
Criscione, V. D., Weinstock, M. A., Naylor, M. F., Luque, C., Eide, M. J., Bingham, S. F., et al. (2009). Actinic keratoses. Cancer, 115(11), 2523–2530.PubMedCrossRef
25.
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., et al. (1994). Sunburn and p53 in the onset of skin cancer. Nature, 372(6508), 773–776. doi:10.​1038/​372773a0.PubMedCrossRef
26.
Ortonne, J. P. (2002). From actinic keratosis to squamous cell carcinoma. British Journal of Dermatology, 146, 20–23.PubMedCrossRef
27.
Nakazawa, H., English, D., Randell, P. L., Nakazawa, K., Martel, N., Armstrong, B. K., et al. (1994). UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proceedings of the National Academy of Sciences of the United States of America, 91(1), 360–364.PubMedCrossRef
28.
29.
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., et al. (1991). A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 88(22), 10124–10128.PubMedCrossRef
30.
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356(6366), 215–221. doi:10.​1038/​356215a0.PubMedCrossRef
31.
Jiang, W., Ananthaswamy, H. N., Muller, H. K., & Kripke, M. L. (1999). p53 protects against skin cancer induction by UV-B radiation. Oncogene, 18(29), 4247. Article.PubMedCrossRef
32.
Matsumoto, T., Jiang, J., Kiguchi, K., Ruffino, L., Carbajal, S., Beltrán, L., et al. (2003). Targeted expression of c-Src in epidermal basal cells leads to enhanced skin tumor promotion, malignant progression, and metastasis. Cancer Research, 63(16), 4819–4828.PubMed
33.
Kiguchi, K., Bol, D., Carbajal, S., Beltrán, L., Moats, S., Chan, K., et al. (2000). Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene, 19(37), 4243. Article.PubMedCrossRef
34.
Zhao, L., Li, W., Marshall, C., Griffin, T., Hanson, M., Hick, R., et al. (2009). Srcasm inhibits Fyn-induced cutaneous carcinogenesis with modulation of Notch1 and p53. Cancer Research, 69(24), 9439–9447.PubMedCrossRef
35.
36.
Pierceall, W. E., Goldberg, L. H., Tainsky, M. A., Mukhopadhyay, T., & Ananthaswamy, H. N. (1991). Ras gene mutation and amplification in human nonmelanoma skin cancers. Molecular Carcinogenesis, 4(3), 196–202.PubMedCrossRef
37.
Spencer, J. M., Kahn, S. M., Jiang, W., DeLeo, V. A., & Weinstein, I. B. (1995). Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Archives of Dermatology, 131(7), 796–800.PubMedCrossRef
38.
39.
Tarutani, M., Cai, T., Dajee, M., & Khavari, P. A. (2003). Inducible activation of Ras and Raf in adult epidermis. Cancer Research, 63(2), 319–323.PubMed
40.
Scholl, F. A., Dumesic, P. A., & Khavari, P. A. (2004). Mek1 alters epidermal growth and differentiation. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Cancer Research, 64(17), 6035–6040.PubMedCrossRef
41.
Quadros, M. R. D., Peruzzi, F., Kari, C., & Rodeck, U. (2004). Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Research, 64(11), 3934–3939.PubMedCrossRef
42.
Suiqing, C., Min, Z., & Lirong, C. (2005). Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. [Comparative Study Research Support, Non-U.S. Gov't]. Journal of Dermatology, 32(5), 354–360.PubMed
43.
Kim, D. J., Angel, J. M., Sano, S., & DiGiovanni, J. (2009). Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene, 28(7), 950–960.PubMedCrossRef
44.
Chan, K. S., Sano, S., Kataoka, K., Abel, E., Carbajal, S., Beltran, L., et al. (2008). Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene, 27(8), 1087–1094.PubMedCrossRef
45.
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 220–241.CrossRef
46.
Becker, J. C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., & Reisfeld, R. A. (2010). Mouse models for melanoma: a personal perspective. Experimental Dermatology, 19(2), 157–164.PubMedCrossRef
47.
Kunisada, T., Lu, S.-Z., Yoshida, H., Nishikawa, S., Nishikawa, S.-i., Mizoguchi, M., et al. (1998). Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. The Journal of Experimental Medicine, 187(10), 1565–1573.PubMedCrossRef
48.
Yamazaki, F., Okamoto, H., Matsumura, Y., Tanaka, K., Kunisada, T., & Horio, T. (2005). Development of a new mouse model (xeroderma pigmentosum A-deficient, stem cell factor-transgenic) of ultraviolet B-induced melanoma. The Journal of Investigative Dermatology, 125(3), 521–525.PubMedCrossRef
49.
Damsky, W. E., Jr., & Bosenberg, M. (2010). Mouse melanoma models and cell lines. Pigment Cell & Melanoma Research, 23(6), 853–859.CrossRef
50.
Mintz, B., & Silvers, W. K. (1993). Transgenic mouse model of malignant skin melanoma. Proceedings of the National Academy of Sciences of the United States of America, 90(19), 8817–8821.PubMedCrossRef
51.
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., et al. (1997). Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes & Development, 11(21), 2822–2834.CrossRef
52.
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Molecular and Cellular Biology, 21(6), 2144–2153.PubMedCrossRef
53.
Hacker, E., Muller, H. K., Irwin, N., Gabrielli, B., Lincoln, D., Pavey, S., et al. (2006). Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice. Cancer Research, 66(6), 2946–2952.PubMedCrossRef
54.
Kannan, K., Sharpless, N. E., Xu, J., O’Hagan, R. C., Bosenberg, M., & Chin, L. (2003). Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proceedings of the National Academy of Sciences of the United States of America, 100(3), 1221–1225.PubMedCrossRef
55.
Sotillo, R., Garcia, J. F., Ortega, S., Martin, J., Dubus, P., Barbacid, M., et al. (2001). Invasive melanoma in Cdk4-targeted mice. [Research Support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America, 98(23), 13312–13317.PubMedCrossRef
56.
Powell, M. B., Hyman, P., Bell, O. D., Balmain, A., Brown, K., Alberts, D., et al. (1995). Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Molecular Carcinogenesis, 12(2), 82–90.PubMedCrossRef
57.
58.
Goel, V. K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., et al. (2009). Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene, 28(23), 2289–2298.PubMedCrossRef
59.
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., et al. (2009). Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell, 15(4), 294–303.PubMedCrossRef
60.
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky, W. E., Jr., et al. (2009). BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genetics, 41(5), 544–552. doi:10.​1038/​ng.​356.PubMedCrossRef
61.
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., et al. (2003). High frequency of BRAF mutations in nevi. Nature Genetics, 33(1), 19–20. doi:10.​1038/​ng1054.PubMedCrossRef
62.
Patton, E. E., Widlund, H. R., Kutok, J. L., Kopani, K. R., Amatruda, J. F., Murphey, R. D., et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current Biology, 15(3), 249–254.PubMedCrossRef
63.
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature, 436(7051), 720–724. doi:10.​1038/​nature03890.PubMedCrossRef
64.
Gruis, N. A., Van der Velden, P. A., Sandkuijl, L. A., Prins, D. E., Weaver-Feldhaus, J., Kamb, A., et al. (1995). Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genetics, 10(3), 351–353.PubMedCrossRef
65.
Ruiz, A., Puig, S., Malvehy, J., Lázaro, C., Lynch, M., Gimenez-Arnau, A. M., et al. (1999). CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. Journal of Medical Genetics, 36(6), 490–493.PubMed
66.
Goldstein, A. M., Chan, M., Harland, M., Hayward, N. K., Demenais, F., Bishop, D. T., et al. (2007). Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. Journal of Medical Genetics, 44(2), 99–106.PubMedCrossRef
Metadata
Title
Reconstructing skin cancers using animal models
Authors
Michael D. Gober
Hasan M. Bashir
John T. Seykora
Publication date
01-06-2013
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1-2/2013
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9410-8

Other articles of this Issue 1-2/2013

Cancer and Metastasis Reviews 1-2/2013 Go to the issue

OriginalPaper

Mouse models of BRCA1 and their application to breast cancer research

OriginalPaper

Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic

OriginalPaper

Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis

NON-THEMATIC REVIEW

Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?

NON-THEMATIC REVIEW

Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications

Erratum

Erratum to: The role of pharmacogenomics in metastatic renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits